0001415889-23-016754.txt : 20231219 0001415889-23-016754.hdr.sgml : 20231219 20231219185854 ACCESSION NUMBER: 0001415889-23-016754 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231215 FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wingrove Theresa CENTRAL INDEX KEY: 0001510720 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 231498919 MAIL ADDRESS: STREET 1: IMMUNOGEN, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 4 1 form4-12192023_111248.xml X0508 4 2023-12-15 0000855654 ImmunoGen, Inc. IMGN 0001510720 Wingrove Theresa C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM MA 02451 false true false false SVP OF REGULATORY AFFAIRS 1 Common Stock 2023-12-15 4 M 0 27788 4.55 A 30599 D Common Stock 2023-12-15 4 M 0 89657 5.32 A 120256 D Common Stock 2023-12-15 4 S 0 117445 29.40 D 2811 D Stock Option (right to buy) 4.55 2023-12-15 4 M 0 27788 0 D 2030-02-07 Common Stock 27788 35871 D Stock Option (right to buy) 5.32 2023-12-15 4 M 0 89657 0 D 2032-02-04 Common Stock 89657 115273 D Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.37 to $29.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges. This option was granted on 2/7/2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years. This option was granted on 2/4/2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years. /s/ Renee Lentini, Attorney-in-Fact 2023-12-19